Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.59 |
| ▸ | HTR2A | P28223 | 5/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.57 |
| ▸ | SCN1A | P35498 | 3/20 | 0.57 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422822 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3HTR2ATAAR1 | |
| SCHEMBL27511961 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL7927468 | 0.98 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL16702791 | 0.98 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL7864529 | 0.98 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3HTR2ATAAR1 | |
| SCHEMBL6890882 | 0.91 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR2ATAAR1 | |
| SCHEMBL6933091 | 0.90 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HTR2ATAAR1 | |
| SCHEMBL22461294 | 0.88 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3HTR2ACHRM2 | |
| SCHEMBL20777760 | 0.88 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3HTR2ATAAR1 | |
| SCHEMBL7073817 | 0.86 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3HTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117165057-A | liquid | 米利肯工业有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-112739758-A | Liquid, method for producing the same and use thereof | 博奇斯催化剂(英国)有限公司 | 2021-04-30 | — | — | CN | claimed |
| CN-107709658-B | Oxidation process | 卡特克塞尔科技有限公司 | 2021-04-09 | — | — | CN | claimed |
| EP-3307940-B1 | OXIDATIVE METHOD | CATEXEL TECH LIMITED (GB) | 2021-03-24 | — | — | EP | claimed |
| CN-108431079-B | Coating composition curable by oxidation | 卡特克塞尔有限公司 | 2020-12-04 | — | — | CN | claimed |
| CN-107709533-B | Oxidation process | 卡特克塞尔科技有限公司 | 2020-09-18 | — | — | CN | claimed |
| EP-2791352-A1 | GABR-A2 DIAGNOSTIC | Astrazeneca AB (SE) | 2014-10-22 | — | — | EP | claimed |
| CN-103459520-A | Antiskinning compositions | OMG UK TECHNOLOGY LTD | 2013-12-18 | — | — | CN | claimed |
| WO-2013088135-A1 | GABR-A2 DIAGNOSTIC | ASTRAZENECA AB (SE) | 2013-06-20 | — | — | WO | claimed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | claimed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | claimed |
| WO-2007017652-A2 | ARYLAKYLAMINES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | claimed |
| EP-1506277-A1 | ENZYMATIC DETERGENT COMPOSITIONS | UNILEVER N.V. (NL) | 2005-02-16 | — | — | EP | claimed |
| WO-2003097780-A1 | ENZYMATIC DETERGENT COMPOSITIONS | UNILEVER N.V. (NL) | 2003-11-27 | — | — | WO | claimed |
| WO-2000063174-A1 | NOVEL PROCESS | ASTRAZENECA AB (SE) | 2000-10-26 | — | — | WO | claimed |
| CN-118215715-A | Method for improving resin properties | 博奇斯有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117165057-A | liquid | 米利肯工业有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-4948802-A | H2 AGONISTS, TREATING HEART DISEASE | HEUMANN PHARMA GMBH & CO. (DE) | 1990-08-14 | — | — | US | disclosed |
| EP-0302164-A1 | Guanidine-carboxylic-acid esters, method for their preparation and medicines containing these compounds | HEUMANN PHARMA GMBH & CO (DE) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | SLC6A2 449/4885SLC6A4 586/4885SLC6A3 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.